This activity is sponsored by

This activity is supported by educational grants from

Christy A. Russell, MD
Associate Professor of Medicine
Co-Director, University of Southern
California/Norris Breast Center,
University of Southern California
Los Angeles, California

Adam M. Brufsky, MD, PhD
Associate Professor of Medicine
Associate Chief, Hematology/Oncology
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania

Ruth M. O’Regan, MD
Associate Professor of Hematology and Medical Oncology
Louisa and Rand Glenn Family Chair in Breast Cancer Research
Director, Hematology/Oncology Fellowship Program
Emory Winship Cancer Institute
Medical Director, Emory Breast Center
Chief of Hematology and Medical Oncology
Georgia Cancer Center for Excellence, Grady Hospital
Atlanta, Georgia

Learning Objectives
Upon completion of this educational activity, participants should be better able to:

• Compare and contrast therapeutic options for patients based on patient- and tumor-specific characteristics
• Discuss updates and advances in therapy regarding treatment and prevention of disease progression in early stage breast cancer
• Describe advances in the development and incorporation of therapies for the management of patients with advanced breast cancer
• Evaluate emerging new therapeutic options for treatment of breast cancer by reviewing ongoing and planned clinical trials

Target Audience
The target audience for The Main Event: 2nd Annual San Antonio Fight Night includes medical oncologists, surgical oncologists, radiation oncologists, pathologists, oncology pharmacists, and allied oncology healthcare providers caring for patients with breast cancer.

Statement of Need
In 2009, breast cancer remains the number one diagnosed cancer and second-leading cause of cancer-related death in US women. An estimated 192,370 new cases of invasive breast cancer will be diagnosed and 40,170 women will die from this disease. The incidence rate of breast cancer peaked in the 1980s and early 1990s increasing by approximately 4% per year until the mid-1990s. Between 1999 and 2006, breast cancer incidence rates decreased by 2% per year. Fortunately, the death rate for women with breast cancer has also declined by approximately 1.9% annually between 1998-2006.

ACCREDITATION INFORMATION

PHYSICIAN CONTINUING EDUCATION
ACCREDITATION STATEMENT
Educational Concepts Group, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
Educational Concepts Group, LLC designates this educational activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

PHARMACIST CONTINUING EDUCATION
	Educational Concepts Group, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Educational Concepts Group, LLC designates this continuing education activity for 2.0 contact hours (0.20 CEUs). (UAN 0199-0000-09-082-H01-P).

Type of activity: Knowledge-based

METHOD OF PARTICIPATION
There are no fees for participating and receiving CME/CE credit for this activity. During the period February 5, 2010 through February 4, 2011, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the post-activity assessment.

The following faculty members have declared relevant financial relationships:

ECG HAS DECLARED THE FOLLOWING FINANCIAL RELATIONSHIPS
ECG receives educational grants from pharmaceutical industry and other commercial sources. Planners, managers, and other staff members at ECG have no relevant financial relationships to disclose.

ACKNOWLEDGEMENT OF COMMERCIAL SUPPORT
This activity is supported by educational grants from Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals and Genentech BioOncology.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Please refer to the official prescribing information for each product or consult the Physicians’ Desk Reference for discussion of approved indications, contraindications, and warnings.

DISCLOSURE OF OFF-LABEL USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. ECG does not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity do not necessarily represent the views of ECG. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

CME/CE INQUIRIES
For further information, please contact:
Educational Concepts Group, LLC 
1300 Parkwood Circle SE, Suite 325
Atlanta, Georgia 30339
Phone: 1.770.933.1681
Fax: 1.770.933.1692
www.educationalconcepts.net

None of the contents may be reproduced in any form without prior written permission from the publisher. This activity may be accessed at www.educationalconcepts.net.